Annual Total Long Term Liabilities
$487.30 M
+$177.03 M+57.06%
01 December 2023
Summary:
Sinovac Biotech annual total long term liabilities is currently $487.30 million, with the most recent change of +$177.03 million (+57.06%) on 01 December 2023. During the last 3 years, it has risen by +$385.71 million (+379.67%). SVA annual total long term liabilities is now at all-time high.SVA Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Long Term Liabilities
$411.49 M
-$75.81 M-15.56%
01 June 2024
Summary:
Sinovac Biotech quarterly total long term liabilities is currently $411.49 million, with the most recent change of -$75.81 million (-15.56%) on 01 June 2024. Over the past year, it has dropped by -$75.81 million (-15.56%). SVA quarterly long term liabilities is now -15.56% below its all-time high of $487.30 million, reached on 01 December 2023.SVA Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SVA Long Term Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -15.6% |
| 3 y3 years | +379.7% | +116.7% |
| 5 y5 years | +2380.3% | +1711.5% |
SVA Long Term Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +379.7% | -15.6% | +116.7% |
| 5 y | 5 years | at high | +3676.1% | -15.6% | +3182.2% |
| alltime | all time | at high | -15.6% |
Sinovac Biotech Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| June 2024 | - | $411.49 M(-15.6%) |
| Dec 2023 | $487.30 M(+57.1%) | $487.30 M(+63.5%) |
| June 2023 | - | $298.13 M(-3.9%) |
| Dec 2022 | $310.27 M(-32.4%) | $310.27 M(-23.8%) |
| June 2022 | - | $407.07 M(-11.4%) |
| Dec 2021 | $459.32 M(+352.1%) | $459.32 M(+141.9%) |
| June 2021 | - | $189.91 M(+86.9%) |
| Dec 2020 | $101.59 M(+687.2%) | $101.59 M(+16.2%) |
| Sept 2020 | - | $87.45 M(+12.3%) |
| June 2020 | - | $77.87 M(+521.1%) |
| Mar 2020 | - | $12.54 M(-2.9%) |
| Dec 2019 | $12.90 M(-34.3%) | $12.90 M(-43.2%) |
| Sept 2019 | - | $22.71 M(+2.2%) |
| June 2019 | - | $22.22 M(-11.1%) |
| Mar 2019 | - | $25.01 M(+27.3%) |
| Dec 2018 | $19.65 M(-33.5%) | $19.65 M(-26.5%) |
| June 2018 | - | $26.74 M(-9.5%) |
| Dec 2017 | $29.54 M(+91.5%) | $29.54 M(+64.0%) |
| June 2017 | - | $18.01 M(+16.8%) |
| Dec 2016 | $15.43 M(+86.2%) | $15.43 M(+52.1%) |
| Sept 2016 | - | $10.14 M(+37.2%) |
| June 2016 | - | $7.39 M(-7.4%) |
| Mar 2016 | - | $7.99 M(-3.6%) |
| Dec 2015 | $8.28 M(-51.2%) | $8.28 M(-43.4%) |
| Sept 2015 | - | $14.65 M(+3.6%) |
| June 2015 | - | $14.14 M(-3.7%) |
| Mar 2015 | - | $14.69 M(-13.4%) |
| Dec 2014 | $16.97 M(-64.6%) | $16.97 M(-44.1%) |
| Sept 2014 | - | $30.34 M(+12.9%) |
| June 2014 | - | $26.88 M(-17.9%) |
| Mar 2014 | - | $32.73 M(-31.7%) |
| Dec 2013 | $47.90 M(-2.6%) | $47.90 M(+17.4%) |
| Sept 2013 | - | $40.80 M(-30.0%) |
| June 2013 | - | $58.25 M(+6.5%) |
| Mar 2013 | - | $54.72 M(+11.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2012 | $49.17 M(+58.2%) | $49.17 M(+41.2%) |
| Sept 2012 | - | $34.83 M(-3.9%) |
| June 2012 | - | $36.23 M(+1.5%) |
| Mar 2012 | - | $35.71 M(+14.9%) |
| Dec 2011 | $31.08 M(+49.1%) | $31.08 M(+1.4%) |
| Sept 2011 | - | $30.66 M(+19.0%) |
| June 2011 | - | $25.77 M(+22.9%) |
| Mar 2011 | - | $20.97 M(+0.6%) |
| Dec 2010 | $20.84 M(+108.5%) | $20.84 M(-15.3%) |
| Sept 2010 | - | $24.61 M(+35.2%) |
| June 2010 | - | $18.21 M(+0.0%) |
| Mar 2010 | - | $18.20 M(+82.0%) |
| Dec 2009 | $10.00 M(+98.9%) | $10.00 M(-20.0%) |
| Sept 2009 | - | $12.49 M(-14.4%) |
| June 2009 | - | $14.58 M(+192.8%) |
| Mar 2009 | - | $4.98 M(-0.9%) |
| Dec 2008 | $5.03 M(+22.5%) | $5.03 M(-23.4%) |
| Sept 2008 | - | $6.56 M(+50.4%) |
| June 2008 | - | $4.37 M(+2.2%) |
| Mar 2008 | - | $4.27 M(+4.2%) |
| Dec 2007 | $4.10 M(+6.9%) | $4.10 M(>+9900.0%) |
| Sept 2007 | - | $0.00(-100.0%) |
| June 2007 | - | $3.93 M(+2.5%) |
| Dec 2006 | $3.84 M(+44.1%) | $3.84 M(+53.5%) |
| June 2006 | - | $2.50 M(-6.2%) |
| Dec 2005 | $2.66 M(+1216.2%) | $2.66 M(+1289.6%) |
| June 2005 | - | $191.70 K(-5.3%) |
| Dec 2004 | $202.40 K(-66.5%) | $202.40 K(-85.5%) |
| Sept 2004 | - | $1.40 M(-34.2%) |
| June 2004 | - | $2.12 M(+251.3%) |
| Dec 2003 | $603.90 K(>+9900.0%) | $603.90 K |
| Apr 2002 | $0.00(-100.0%) | - |
| Apr 2001 | $178.60 K(-63.9%) | - |
| Apr 2000 | $495.00 K(>+9900.0%) | - |
| Apr 1999 | $0.00 | - |
FAQ
- What is Sinovac Biotech annual total long term liabilities?
- What is the all time high annual total long term liabilities for Sinovac Biotech?
- What is Sinovac Biotech quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Sinovac Biotech?
- What is Sinovac Biotech quarterly long term liabilities year-on-year change?
What is Sinovac Biotech annual total long term liabilities?
The current annual total long term liabilities of SVA is $487.30 M
What is the all time high annual total long term liabilities for Sinovac Biotech?
Sinovac Biotech all-time high annual total long term liabilities is $487.30 M
What is Sinovac Biotech quarterly total long term liabilities?
The current quarterly long term liabilities of SVA is $411.49 M
What is the all time high quarterly long term liabilities for Sinovac Biotech?
Sinovac Biotech all-time high quarterly total long term liabilities is $487.30 M
What is Sinovac Biotech quarterly long term liabilities year-on-year change?
Over the past year, SVA quarterly total long term liabilities has changed by -$75.81 M (-15.56%)